Collaboration bridges home and hospital, creating a secure pathway for pediatric insights to be managed and shared.
LEHI, Utah–(BUSINESS WIRE)–$owlt #babymonitor—Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces a partnership with Rhapsody, a global leader in digital health enablement and interoperability, to securely connect infant health insights from Owlet’s FDA-cleared, prescription pulse oximeter, BabySat®, directly into their existing electronic health record (EHR) workflows.
The integration creates a secure, standards-based pathway for Owlet’s pediatric data to flow seamlessly into existing provider environments, enabling clinicians to view and record important data information as part of their standard patient records. With Rhapsody’s flexible integration solution, healthcare organizations can reduce custom development, minimize errors, and ensure accurate, timely patient information is available when and where it’s needed most.
“Our partnership with Rhapsody is another step forward in Owlet’s mission to redefine how infant data is integrated and used more effectively within the healthcare system,” said Jonathan Harris, Owlet’s President and CEO. “We’re connecting the dots between home and hospital by delivering clinically validated infant monitoring that keeps parents and providers connected from anywhere. By integrating with the Rhapsody trusted exchange platform, we’ve made sharing infant health data simple, empowering families to make informed decisions and allowing clinicians to deliver better care.”
By simplifying data connectivity between home and clinical settings, the partnership makes it easier for hospitals to scale their pediatric remote patient monitoring (RPM) programs. Clinicians can access continuous, real-time insights from patients receiving care at home, seamlessly integrated into the tools they already use.
“True interoperability isn’t just about moving data, it’s about making that data meaningful in the moments that matter,” said Sagnik Bhattacharya, CEO of Rhapsody. “By connecting Owlet’s clinically-validated monitoring data directly into the EHR, we’re giving clinicians a fuller view of their youngest patients, and helping families feel more connected to their child’s care team.”
This integration marks a key milestone in Owlet’s expansion into clinical settings and reflects growing interest in connected monitoring from healthcare systems nationwide. As Owlet continues to bridge the gap between home monitoring and hospital care, the Company remains focused on empowering parents and providers with trusted, clinically validated insights. To learn more about Owlet’s FDA-cleared products, including BabySat and Dream Sock®, visit www.owletcare.com.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children’s well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
About Rhapsody
Rhapsody is a global leader in healthcare interoperability and digital health enablement infrastructure serving over 1,900 customers. Rhapsody enables care providers, health tech builders, and public health teams to save time, reduce costs, and recognize revenue more quickly by accelerating adoption of digital health innovation through interoperability. Rhapsody API-enabled solutions are composable and flexible to meet customers where they are, deployable in a private cloud, Rhapsody cloud, or as an iPaaS.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expectations regarding the outcomes and benefits of Owlet’s partnership with Rhapsody and the integration of infant health insights from BabySat® into electronic health record (EHR) workflows, including potential improvements in interoperability, data connectivity and clinical workflows; the scope, timing, adoption and performance of the integration; the ability of healthcare providers to scale remote patient monitoring programs and access real-time insights; the Company’s product roadmap and growth prospects; and potential market reception and competitive positioning. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the commercial success of BabySat, related software and services, and the Rhapsody-enabled integration; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iii) the Company’s and its partners’ obligations relating to data privacy, security and interoperability (including HIPAA, HITECH and comparable laws, and evolving standards such as HL7/FHIR and information-blocking/interoperability requirements), and risks of cybersecurity incidents or changes in applicable standards or interpretations; (iv) the performance of, and Owlet’s ability to maintain and expand, its relationship with Rhapsody and other third-party technology, cloud, manufacturing and distribution partners; (v) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, successfully execute and support integrations with third-party systems, innovate and enhance existing products, meet customer demands and adapt to changes in consumer and provider preferences and retail and healthcare trends; (vii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (viii) Owlet’s ability to maintain relationships with healthcare providers and health systems, channel partners, customers, manufacturers and suppliers; (ix) impacts from compliance with applicable laws or regulations; (x) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xi) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences, evolution of reimbursement and remote patient monitoring programs; and (xii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
Contacts
Owlet Media Contact:
[email protected]
Owlet Investor Contact:
[email protected]
Owlet Health Contact:
[email protected]
Rhapsody Contact:
[email protected]
